SLDB — Solid Biosciences Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1707502 ·
Last close
$6.88
Market Cap
$677.33M
52W High
$8.87
52W Low
$5.52
ADV30
1,087,477
Next earnings
2026-08-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -57,308,000 | -56,737,000 | 422,893,000 | 297,099,000 | 48,761,000 |
| Dec 2025 | 0 | — | -49,403,000 | -49,787,000 | 232,540,000 | 59,900,000 | 52,530,000 |
| Sep 2025 | 0 | — | -48,058,000 | -45,776,000 | 273,914,000 | 61,364,000 | 55,966,000 |
| Jun 2025 | 0 | — | -41,693,000 | -39,480,000 | 308,292,000 | 138,933,000 | 50,001,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-156,289,000
Investing CF
$-58,454,000
Financing CF
$194,446,000
CapEx
$-1,153,000
Dividends Paid
—
Buybacks
$-1,681,000
EPS Diluted TTM
$-2.28
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-957,775,000
Inventory
—
Receivables
—
ST Investments
$127,950,000
EBIT TTM
$-176,095,000
Pretax Income TTM
$-174,325,000
Interest Exp TTM
$285,000
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -179,206,000 | -174,325,000 | 232,540,000 | 52,530,000 | — | -156,289,000 |
| Dec 2024 | 0 | -129,728,000 | -124,697,000 | 188,662,000 | 51,416,000 | — | -100,012,000 |
| Dec 2023 | 0 | -104,315,000 | -96,015,000 | 164,939,000 | 38,458,000 | — | -94,180,000 |
| Dec 2022 | 8,094,000 | -99,274,000 | -85,981,000 | 260,252,000 | 48,586,000 | — | -97,977,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.93
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | $731.73M | $2.12 | — |
| CABA | Cabaletta Bio, Inc. | $606.56M | $3.72 | — |
| CKDXF | Opthea Ltd | $601.91M | $0.44 | — |
| VOR | Vor Biopharma Inc. | $764.02M | $14.10 | — |
| AURA | Aura Biosciences, Inc. | $786.77M | $7.61 | — |
News headlines (Yahoo Finance, 1h cache)
Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?
2026-05-20 12:36 · Yahoo
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-12 20:08 · Yahoo
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
2026-05-07 12:00 · Yahoo
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-01 20:05 · Yahoo
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
2026-04-30 12:00 · Yahoo
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
2026-04-28 12:00 · Yahoo
Solid Biosciences to Participate at Upcoming Investor Conferences
2026-04-07 12:00 · Yahoo
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
2026-03-19 20:12 · Yahoo
Solid Biosciences says interim results reinforce confidence in SGT-003 potential
2026-03-12 17:10 · Yahoo
Stock Market Today, March 11: Oracle Surges as Markets Weigh Geopolitical Risks
2026-03-11 21:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.